Trevi Therapeutics Inc Asset Resilience Ratio
Trevi Therapeutics Inc asset resilience ratio. Trevi Therapeutics Inc (TRVI) has an Asset Resilience Ratio of 80.05% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Trevi Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Trevi Therapeutics Inc (2016–2025)
Asset resilience ratio of Trevi Therapeutics Inc from 2016 to 2025. This chart shows how Trevi Therapeutics Inc's Asset Resilience Ratio has changed over time. See financial agility of Trevi Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Trevi Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see TRVI current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $264.57 Million | 80.05% |
| Total Liquid Assets | $264.57 Million | 80.05% |
Asset Resilience Insights
- Very High Liquidity: Trevi Therapeutics Inc maintains exceptional liquid asset reserves at 80.05% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Trevi Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Trevi Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Trevi Therapeutics Inc Asset Resilience Ratio by Year (2016–2025)
Trevi Therapeutics Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Trevi Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 87.54% | $169.35 Million | $193.44 Million | +21.25pp |
| 2024-12-31 | 66.30% | $73.53 Million | $110.90 Million | +9.73pp |
| 2023-12-31 | 56.57% | $50.57 Million | $89.40 Million | -31.16pp |
| 2022-12-31 | 87.73% | $107.92 Million | $123.02 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $38.48 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $20.49 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $22.23 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $8.41 Million | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more